RxDoctor Payments Data

Charles Welly, DO

Family Medicine · Fincastle, VANPI 1700956414

Payments from drug & device makers

$1,503in general payments, 2019–2025

Across 84 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$324
  • Boehringer Ingelheim$198
  • Amgen$187
  • Amarin Pharma, Inc.$153
  • GSK$130
  • Lilly USA, LLC$119
  • plus $393 from 10 others

What the payments were for

  • Food & beverage$1,48399%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,503 in reported general payments places this provider in the 70th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$257,079
Medicare patients
312
Services billed
1,589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban405$130,286
BetaseronInterferon Beta-1b19$97,921
XareltoRivaroxaban87$23,584
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$21,179
TrulicityDulaglutide13$13,505
JardianceEmpagliflozin34$11,486
OzempicSemaglutide11$10,437
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$9,712
Memantine Hcl168$7,516
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$6,508
Midodrine Hcl30$4,945
Levothyroxine Sodium311$4,870
TrintellixVortioxetine Hydrobromide20$4,697
Atorvastatin Calcium318$4,541
Incruse ElliptaUmeclidinium Bromide13$4,452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$101$130,286405 claims
BayerBetaseron$18$97,92119 claims
GSKTrelegy Ellipta, Incruse Ellipta$130$25,63144 claims
Johnson & JohnsonXarelto$30$23,58487 claims
Lilly USA, LLCTrulicity$119$13,50513 claims
Boehringer IngelheimJardiance$198$11,48634 claims
AstraZenecaBreztri Aerosphere$324$9,71214 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$38$4,69720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Fincastle

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →